Skip to content
⌘KStart free
AI InfrastructureDefenseQuantumAll studies →

Study of INKmune in Patients With mCRPC (CaRe Prostate)

← catalyst calendar

NCT06056791

Sponsored by Inmune Bio, Inc. (industry) · INMB — their whole pipeline →.

Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
12actual
Sites
8
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-11-30actualWhen the study began enrolling
Primary completion2025-09-10actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-09-10actualThe whole study's end, after follow-up
First posted2023-09-28actualWhen this record first appeared on the registry
Results posted—When the sponsor posted results to the registry
Record updated2026-02-27actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • mCRPC

Intervention

  • Biological: INKmune

Primary outcomes

what the primary-completion date above is the date OF
Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
measured 2-3 years
Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
measured 2-3 years
Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
measured 2-3 years
Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
measured 2-3 years
Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
measured 2-3 years
Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
measured 2-3 years
Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
measured 2-3 years
Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
measured 2-3 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · INMB's whole pipeline · Catalyst calendar · Every registered study · What changed

Related →Calendar (CAL)Screener (SCR)Watchlist (WL)